Results 71 to 80 of about 35,844 (248)

Adaptive immunity in cancer immunology and therapeutics. [PDF]

, 2014
Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
Lockley, M, Spurrell, EL
core   +2 more sources

Effectiveness and Safety of Radium‐223 for Bone‐Metastatic Castration‐Resistant Prostate Cancer: The KYUCOG‐1901 Study

Cancer Science, EarlyView.
The KYUCOG‐1901 prospective multicenter study evaluated radium‐223 in 93 Japanese patients with bone‐metastatic castration‐resistant prostate cancer. Ra‐223 was well tolerated, produced meaningful declines in ALP, and yielded a median overall survival of 23.0 months. Early initiation in patients with lower disease burden and integration with subsequent
Masaki Shiota, Shuichi Tatarano, Tomomi Kamba, Toshiyuki Kamoto, Tsukasa Igawa, Naoya Masumori, Hirotsugu Uemura, Kensuke Mitsunari, Takayuki Sumiyoshi, Hiroji Uemura, Katsuyoshi Higashijima, Shoji Tokunaga, Masatoshi Eto   +12 more
wiley   +1 more source

Routine use of denosumab for prevention of skeletal-related events in patients with bone metastases from prostate carcinoma in Bulgaria: a prospective observational study

Biotechnology & Biotechnological Equipment
Bulgarian real-world data on denosumab use for the prevention of skeletal-related events (SREs) associated with bone metastases (BM) from prostate cancer (PC) are lacking.
Antoaneta Tomova, Valentina Ianakieva, Katja Bjorklof, Adrian Olszewski, Miglena Petrova   +4 more
doaj   +1 more source

Denosumab Can Prevent Collapse in Patients with Early‐Stage Steroid‐Induced Osteonecrosis of the Femoral Head by Inhibiting Osteoclasts and Autophagy

Orthopaedic Surgery, 2023
Objective The osteoclastic bone resorption inhibitors might have positive effect in preventing femoral head collapse in patients with osteonecrosis of the femoral head (ONFH).
Bo Liu, Feng Gao, Xiaofei Xiu, Tao Wu, Zeming Liu, Bingshi Zhang, Sikai Liu, Yongtai Han   +7 more
doaj   +1 more source

Incidence and Risk Factors of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients Having Undergone Autologous Stem Cell Transplantation [PDF]

, 2012
Background: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a severe complication of bisphosphonate therapy. Due to their long survival and subsequently high cumulative doses of bisphosphonates, multiple myeloma patients have the highest risk ...
Baumann, Philipp, Bumeder, Irmgard, Hörauf, Natalie, Oduncu, Fuat S., Otto, Sven, Pautke, Christoph, Röhnisch, Tim, Schmidmaier, Ralf, Then, Cornelia, Tresckow, Emmo von   +9 more
core   +1 more source

Clinical Practice Patterns in Bone Health Assessment and Management in Endogenous Cushing's Syndrome

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Skeletal fragility is a common complication of endogenous Cushing's Syndrome (CS), although specific guidelines for managing bone health are lacking. This study aimed to assess clinicians' current engagement with bone health assessment and management in patients with endogenous CS. Design Retrospective‐cohort design. Patients Seventy‐
Preeshila Behary, Dinushan Raveendran, Ramesh Nair, Aimee Di Marco, Debbie Papadopoulou, Florian Wernig, Ali Abbara, Karim Meeran, Niamh Martin, Jeremy Cox, Alexander N. Comninos   +10 more
wiley   +1 more source

Effects of 3-year denosumab treatment on hip structure in Japanese postmenopausal women and men with osteoporosis

Bone Reports, 2017
Denosumab, a human monoclonal antibody against RANK ligand, is shown to have strong anti-fracture effects in Japanese osteoporosis patients. However, there have been no data showing actions on Japanese bone architecture.
Teruki Sone, Naohiro Kon, Kenneth W. Gaither, Naoki Okubo, Taisuke Osakabe, Yutaka Nakayama, Masao Fukunaga, Masako Ito, Toshitaka Nakamura   +8 more
doaj   +1 more source

Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO. [PDF]

, 2017
Antiosteoporotic drugs are recommended in patients with fragility fractures and in patients considered to be at high fracture risk on the basis of clinical risk factors and/or low bone mineral density.
Aubry-Rozier, B., Birkhäuser, M., Bischoff-Ferrari, H.A., Ferrari, S., Frey, D., Kressig, R.W., Lamy, O., Lippuner, K., Meier, C., Stute, P., Suhm, N., Uebelhart, B.   +11 more
core   +4 more sources

Alterations of bone proteins in medication‐related osteonecrosis of the jaw

European Journal of Oral Sciences, Volume 133, Issue 2, April 2025.
Abstract Changes in the protein expression pattern of osteoblastic lineage cells from the alveolar bone (OLAB) during medication‐related osteonecrosis of the jaw (MRONJ) have rarely been investigated. This lack of information is partly because of the limited availability of healthy samples and the lack of human alveolar bone cell lines for research ...
Andrea Schubert, Phillipp Brockmeyer, Philipp Kauffmann, Jan Wiegel, Florian Lautenbacher, Nicolai Miosge, Boris Schminke   +6 more
wiley   +1 more source

Cardiovascular Safety in Postmenopausal Women and Men With Osteoporosis Treated With Denosumab and Zoledronic Acid: A Post‐Authorization Safety Study [PDF]

, 2023
Leslie Spangler, Carrie M. Nielson, M. Alan Brookhart, Rohini K. Hernandez, Robert Stad, Tzu‐Chieh Lin   +5 more
openalex   +1 more source